Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center
-
Published:2024-07
Issue:7
Volume:5
Page:100696
-
ISSN:2666-3643
-
Container-title:JTO Clinical and Research Reports
-
language:en
-
Short-container-title:JTO Clinical and Research Reports
Author:
Dehar NavdeepORCID,
Meem Mahbuba,
Aggarwal Ishita,
Hopman Wilma,
Gaudreau Pierre-Olivier,
Robinson Andrew,
Fung Andrea S.
Reference12 articles.
1. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018
2. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133);Liu;J Clin Oncol,2021
3. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019
4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial;Goldman;Lancet Oncol,2021
5. Impact of broadening trial eligibility criteria for patients with advanced non-small cell lung cancer: real-world analysis of select ASCO-friends recommendations;Harvey;Clin Cancer Res,2021